Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Eriksson, 2006, Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery, Drugs, 66, 1411, 10.2165/00003495-200666110-00001

Weitz, 2006, Emerging anticoagulants for the treatment of venous thromboembolism, Thromb Haemost, 96, 274, 10.1160/TH06-05-0234

Anderson, 2003, Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry, Chest, 124, 349S, 10.1378/chest.124.6_suppl.349S

Tapson, 2005, Antithrombotic therapy practices in US hospitals in an era of practice guidelines, Arch Intern Med, 165, 1458, 10.1001/archinte.165.13.1458

Ansell, 2004, The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 204S, 10.1378/chest.126.3_suppl.204S

Stassen, 2001, Identification and in vitro characterization of BIBR 953 ZW, a novel synthetic low molecular weight direct thrombin inhibitor, Thromb Haemost, 86, P755

Hauel, 2002, Structure‐based design of novel potent nonpeptide thrombin inhibitors, J Med Chem, 45, 1757, 10.1021/jm0109513

Stangier, 2005, Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement, J Clin Pharmacol, 45, 555, 10.1177/0091270005274550

Liesenfeld, 2006, Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis, Br J Clin Pharmacol, 62, 527, 10.1111/j.1365-2125.2006.02667.x

Eriksson, 2005, A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial, J Thromb Haemost, 3, 103, 10.1111/j.1538-7836.2004.01100.x

Rabinov, 1972, Roentgen diagnosis of venous thrombosis in the leg, Arch Surg, 104, 134, 10.1001/archsurg.1972.04180020014004

Kalebo, 1996, Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment, Thromb Haemost, 76, 893, 10.1055/s-0038-1650682

Kalebo, 1997, Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials, Acta Radiol, 38, 320, 10.1080/02841859709172072

2000

Geerts, 2001, Prevention of venous thromboembolism, Chest, 119, 132S, 10.1378/chest.119.1_suppl.132S

Eriksson, 2003, Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement, Thromb Haemost, 89, 288, 10.1055/s-0037-1613445

Eriksson, 2003, The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study, J Thromb Haemost, 1, 2490, 10.1111/j.1538-7836.2003.00494.x

Leclerc, 1992, Prevention of deep vein thrombosis after major knee surgery – a randomized, double‐blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo, Thromb Haemost, 67, 417, 10.1055/s-0038-1648463

Marcus, 1976, On closed testing procedures with special reference to ordered analysis of variance, Biometrika, 63, 655, 10.1093/biomet/63.3.655

2000

Lotke, 2005, Deep venous thrombosis prophylaxis: better living through chemistry – in opposition, J Arthroplasty, 20, 15, 10.1016/j.arth.2005.03.002

FDA Working Group. CDER‐PhRMA‐AASLD Conference 2000: clinical white paper on drug‐induced hepatotoxicity. Rockville: Food and Drug Administration, November 2000. http://www.fda.gov/cder/livertox/clinical.pdf. (accessed January 15, 2007).

Eriksson, 2007, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial, Lancet, 370, 949, 10.1016/S0140-6736(07)61445-7

Friedman, 2007, Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty [abstract], J Thromb Haemost, 5, OC051